Objectives: Eradication therapy selection for Helicobacter pylori gastritis requires knowledge of the local resistance rate to clarithromycin. There is minimal population-based or regional data in the United States on pediatric clarithromycin resistance. Although commercial methods such as fluorescence in situ hybridization and DNA probe assays are available in Europe for the evaluation of H pylori 23S rRNA mutations associated with resistance, clinical testing for 23S rRNA in the United States is not widely available. This study examined a single pediatric institution's clarithromycin resistance rate by a DNA polymerase chain reaction/sequencing assay applied to archived gastric biopsy specimens. Methods: From the period 2010 to 2012, 38 H pylori-infected gastric biopsies were examined from archived formalin-fixed paraffin-embedded (FFPE) material. The 23S rRNA gene of H pylori was polymerase chain reaction amplified and sequenced for the identification of point mutations that are associated with clarithromycin therapeutic resistance. Results: By 23S rRNA gene sequencing, 50% (n ¼ 19) of the specimens contained H pylori with mutations significant for clarithromycin resistance. Conclusions: This study is consistent with other pediatric reports suggesting significant H pylori clarithromycin resistance in the United States. Furthermore, the method used in this study can be used by hospitalbased clinical laboratories to assess local clarithromycin resistance from archived biopsy material.
H elicobacter pylori infection is the major cause of gastric ulcer disease and gastritis and a risk factor in the development of gastric cancer. The estimated H pylori infection prevalence is 80% to 90% in developing countries and 35% to 40% in the United States (1) . Clarithromycin-based triple therapy is often used as the first-line therapy, but resistance to clarithromycin has been increasing worldwide, leading to eradication failure. European and American pediatric gastroenterology societies (the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition) (2) consider a high prevalence of resistance to be >20%, and pediatric gastroenterology guidelines recommend antibiotic susceptibility testing in areas of high resistance rate. Resistance to clarithromycin is caused by the presence of point mutations in domain V of the 23S rRNA gene of H pylori. The analysis of the 23S rRNA gene has been demonstrated to have a 91.5% correlation with minimum inhibitory concentration (MIC) by E test for the detection of resistance (3) .
Studies have reported a clarithromycin resistance rate of 10% to 13% in adult populations (1,4), but only a few studies have reported clarithromycin resistance in pediatric populations. Pediatric studies in the United States have described a resistance rate of 38% to 41% (5, 6) . In a recent study of Japanese pediatric patients, the resistance rate was reported to be 36% (7) , and a recent European multicenter study reported a resistance rate of 32% in children (8) .
In this report, the clarithromycin resistance rate in a tertiary care pediatric hospital was investigated using a novel DNA polymerase chain reaction (PCR)/sequencing assay targeted to domain V of the 23S rRNA gene of H pylori.
METHODS

Patient Population and Materials
The study was performed according to a protocol approved by the University of Texas Southwestern Medical Center institutional review board. Patient data, archived slides, and formalinfixed paraffin-embedded (FFPE) blocks were obtained from Children's Medical Center (Dallas, TX). The electronic medical records were reviewed for all cases. A search of the laboratory information system from 2010 to 2012 was performed for gastric biopsies with reports either positive or negative for H pylori gastritis. Specimens that were negative for H pylori were examined to demonstrate the specificity of the PCR/sequencing assay. All specimens had been previously analyzed by hematoxylin and eosin stain, and immunohistochemistry (IHC) specific for H pylori.
DNA Extraction From FFPE Samples
Human and bacterial DNA were extracted from 20-mm FFPE sections. Either 2 or 5 sections were obtained depending on the amount of tissue present in the block. The QIAamp DNA FFPE Tissue Kit (QIAGEN, Valencia, CA) was used and the DNA was eluted in 40 mL. The number of paraffin sections used was inversely proportional to the amount of tissue present in the block.
Primer Design
Primers were designed in highly conserved regions of the 23S rRNA gene domain V of H pylori targeting the mutation sites. To 
Specificity of the Primers
The primers were tested against different bacterial and fungal isolates to evaluate potential cross-reactivity. The bacterial 16S rRNA gene and the fungal ITS sequence were amplified as positive controls.
PCR Amplification, Sequencing, and Mutation Analysis
The extracted DNA was PCR-amplified using the HotStarTaq Plus Master Mix (QIAGEN) and sequenced on the 3130xl Genetic Analyzer (Life Technologies, Foster City, CA). Human b-actin gene was used as an internal control to check for the quality of the extracted DNA sample. The sequencing results were compared with the reference sequence GenBank: U27270.1 using Mutation Surveyor (SoftGenetics, State College, PA).
RESULTS
Case Selection
During the 3-year period 2010 through 2012, a total of 4089 patients underwent gastric biopsies at our pediatric institution. H pylori was identified in 4.5% (n ¼ 184) of these gastric biopsies by histology and/or IHC. Thirty-eight H pylori positive FFPE specimens were examined. Positive cases were selected as consecutive groups with the following distribution by year: 2010, 5 cases; 2011, 5 cases; and 2012, 28 cases. In addition, 15 consecutive gastric biopsy cases that were negative for H pylori were examined as analytical controls. 
Specificity of the Primers
No cross-reactivity of the primers was detected with the following bacterial organisms: Staphylococcus aureus, S epidermidis, Pseudomonas aeruginosa, Bacteroides fragilis, Salmonella spp, Lactobacillus spp, Clostridium spp, Campylobacter jejuni, group A Streptococcus, S mitis, Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Proteus mirabilis, and the following fungal isolates: Fusarium spp, Trichosporon spp, and Candida spp.
Two gastric biopsy cases with a diagnosis of H heilmannii were examined by the H pylori 23S rRNA assay. The PCR amplification revealed cross-reactivity of the primers; however, by sequencing the PCR product, no mutations associated with clarithromycin resistance were identified, and the identity was determined to be Candidatus Helicobacter felis (data not shown).
Limit of Detection, Sensitivity, and Specificity
The limit of detection of the PCR reaction was 50 fg based on serial dilutions of purified DNA from the American Type Culture Collection H pylori strain 26695. The sensitivity and specificity of the PCR/sequencing assay were 100% as compared with IHC when the samples contained a bacterial load of !48 H pylori organisms on a representative single 5-mm-stained tissue section.
Detection of Nucleotide Substitutions
Seven different nucleotide substitutions were identified in H pylori-positive samples: C2131T, A2142G, A2143G, T2182C, A2187G, A2222G, and A2223G. Of these, only 2 substitutions, A2142G and A2143G, have been consistently correlated with clarithromycin resistance in previously published studies. We identified the A2142G or A2143G mutation in 19 of the 38 H pylori-positive cases (50%) ( Table 1 ).
Patients' Characteristics
The patients' ages ranged from 3 to 19 years old (Table 1) . There were 18 girls and 20 boys. Of these 38 patients with H pylori infection, 86.8% (n ¼ 33) had endoscopic findings of gastritis (eg, nodular gastric mucosa, erythema, erosions). All of the patients with H pylori infection were symptomatic with gastrointestinal symptoms (eg, abdominal pain, nausea, vomiting, diarrhea).
Of the 19 cases that had a 23S mutation, 17 were A2143G and 2 were A2142G ( Fig. 1 and Table 1 ). Six of the 19 patients with 23S mutant H pylori had prior antibiotic exposure. Two of the 6 patients with prior antibiotic exposure had been previously treated in the outpatient setting for H pylori gastritis with a regimen of clarithromycin, amoxicillin, and prevacid. Fifteen of the 19 mutant cases were treated with a clarithromycin combination therapy; the other 4 cases were treated with regimens including metronidazole. Of the 15 mutant 23S cases treated with clarithromycin, 3 had no follow-up information. The remaining 12 mutant 23S cases were cured by clarithromycin, amoxicillin, and Prevacid in only 4 cases (33.3% cure using clarithromycin regimen). Of the 8 cases that failed clarithromycin-based therapy, 5 were treated with a second antibiotic combination regimen based on either clarithromycin (n ¼ 2) or metronidazole (n ¼ 3). Both patients on a second regimen based on clarithromycin failed therapy again. Two of 3 patients on a second regimen based on metronidazole were cured.
Five of the 19 patients with infection by wild-type H pylori had prior antibiotic exposure ( Table 1 ). Two of the 5 patients with prior antibiotic exposure had been previously treated for H pylori gastritis with a regimen of clarithromycin, amoxicillin, and prevacid. Eleven of the 19 patients were treated with a clarithromycin combination therapy; the other 8 patients were treated with regimens including metronidazole. Three of the patients with wild-type H pylori were treated with clarithromycin and had no follow-up information. Of the remaining 8 patients with wild-type H pylori infection, 5 had cure by a clarithromycin regimen (62.5%). The remaining 3 patients with wild-type H pylori infection failed clarithromycin-based therapy and have not been started on a second antibiotic regimen.
DISCUSSION
The assay described in our study detects H pylori mutations that are associated with clarithromycin resistance. Fifty percent of the H pylori-infected patients had the A2142G or A2143G mutation. This rate of clarithromycin resistance is much higher than the rates seen in the last national surveys of the United States (1,4), which reported no geographic region with a resistance rate of greater than 15%. The overall concordance between clarithromycin resistance by E test and the presence of 23S rRNA gene mutations is 81% to 91% (3, 9) . Considering phenotypic resistance testing as the criterion standard, a report demonstrated that the sensitivity and specificity of point mutations at positions 2142 and 2143 were 75% and 98.3%, respectively (10) . Some studies have noted that the mutation A2143G is associated with high MIC values (3, 11) , whereas others have found high MIC values associated with the A2142G mutation (12) (13) (14) .
The eradication rate by clarithromycin combination therapy (clarithromycin, amoxicillin, and Prevacid) in our patient population infected with wild-type H pylori was 62.5%. This rate is lower than the previously published rates of approximately 83% (15, 16) . Possible explanations include poor patient compliance, amoxicillin resistance, or clarithromycin resistance not detected by 23S rRNA gene mutation analysis.
The PCR/sequencing method used in this study is designed to test FFPE samples. This method allows for the identification of mutant H pylori strains before initiation of clarithromycin therapy. This is especially relevant in areas of high clarithromycin resistance rates or in patients refractory to H pylori therapy. Furthermore, the flexibility of testing archived FFPE samples will enable hospitalbased clinical laboratories to rapidly determine their local clarithromycin resistance rate and will aid in the management of antibiotic-resistant H pylori gastritis.
